A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

Aimee L. McRae-Clark; Rickey E. Carter; Therese K. Killeen; Matthew J. Carpenter; Kathleen G. White; Kathleen T. Brady

doi:10.1111/j.1521-0391.2010.00076.x

A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

Aimee L. McRae-Clark, Rickey E. Carter, Therese K. Killeen, Matthew J. Carpenter, Kathleen G. White, Kathleen T. Brady

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Abstract

This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.

Original language	English (US)
Pages (from-to)	481-489
Number of pages	9
Journal	American Journal on Addictions
Volume	19
Issue number	6
DOIs	https://doi.org/10.1111/j.1521-0391.2010.00076.x
State	Published - Nov 2010

ASJC Scopus subject areas

Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

Access to Document

10.1111/j.1521-0391.2010.00076.x

Cite this

@article{a4e933435ff94b7b8649523b2e87c074,

title = "A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder",

abstract = "This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.",

author = "McRae-Clark, {Aimee L.} and Carter, {Rickey E.} and Killeen, {Therese K.} and Carpenter, {Matthew J.} and White, {Kathleen G.} and Brady, {Kathleen T.}",

year = "2010",

month = nov,

doi = "10.1111/j.1521-0391.2010.00076.x",

language = "English (US)",

volume = "19",

pages = "481--489",

journal = "American Journal on Addictions",

issn = "1055-0496",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

AU - McRae-Clark, Aimee L.

AU - Carter, Rickey E.

AU - Killeen, Therese K.

AU - Carpenter, Matthew J.

AU - White, Kathleen G.

AU - Brady, Kathleen T.

PY - 2010/11

Y1 - 2010/11

N2 - This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.

AB - This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.

UR - http://www.scopus.com/inward/record.url?scp=78349292268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349292268&partnerID=8YFLogxK

U2 - 10.1111/j.1521-0391.2010.00076.x

DO - 10.1111/j.1521-0391.2010.00076.x

M3 - Article

C2 - 20958842

AN - SCOPUS:78349292268

SN - 1055-0496

VL - 19

SP - 481

EP - 489

JO - American Journal on Addictions

JF - American Journal on Addictions

IS - 6

ER -

A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this